Shots:

• The P-III (EMPA-KIDNEY) trial to evaluate Jardiance vs PBO in 6609 adults patients with CKD in 8 countries
• The trial met its 1EPs i.e., the therapy showed a significant kidney & CV benefit, a 28% reduction in risk of kidney disease progression or CV death, a reduction in all-cause hospitalizations (14%), providing potential relief for patients, and a reduced burden on healthcare systems. Additionally, reductions in other key 2EPs of hospitalization for HF or CV death, or all-cause death were not statistically significant
• The safety data were consistent with prior results confirming the well-established safety profile of Jardiance. The results were presented at ASN 2022 by MRC PHRU at the University of Oxford & also published in the NEJM

Ref: Eli Lilly  | Image: Eli Lilly